In this interview with Tony Veverka, Chief Group Executive of BioEden, Mr. Veverka discusses how dental stem cells will impact our future. BioEden is a global stem cell storage company with laboratories in the UK and USA and sales operations in 19 countries. BioEden is also the world’s first international biobank company to collect, assess, and cryogenically store living stem cells from deciduous baby teeth.
How To (Potentially) Avoid ACL Surgery With Stem Cell Treatment
Despite ACL surgeries being more readily available than ever before, torn knee ligaments are still one of the most dreaded injuries for athletes and other active people. The anterior cruciate ligament (ACL) is responsible for stabilizing the knee. If it tears after a sudden wrenching movement, then stability and ease of motion are destroyed. Until recently, ACL surgeries seemed to be the only way for patients to escape the pain, stiffness, and stability loss that comes with an ACL injury.
Fortunately, stem cell treatment may now represent a viable way for some patients to repair torn knee ligaments while avoiding invasive ACL surgeries.
Alternative To ACL Injuries? How Stem Cells Might Help
In this article:
Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics
Fujifilm CDI is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.
The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
AABB’s Cell and Gene Therapy Standards for Pharmacy, First Edition, Takes Effect October 1
Sept 8, 2025, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the release of the first edition of Cell and Gene Therapy Standards for Pharmacy, which take effect Oct. 1, 2025, and are now available for purchase on the AABB Store. These new Standards represent a critical advancement in strengthening quality and safety for cell and gene therapy (CGT) products managed by pharmacies. [Read more…]
Historic Patent Challenges to Pluripotent Stem Cells (ESCs and iPSCs)
The patent landscape for pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), is characterized by groundbreaking discoveries, legal challenges, and debates over accessibility. The patent environment surrounding these stem cell types is complicated, and there are a number of restrictions on how the cells can be used for commercial and strategic purposes. [Read more…]
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 334
- Next Page »